Then why would a UAE hospital reduce readmissions?

Because Abu Dhabi lets you get paid for it. Section 2.4 of the DoH Claims and Adjudication Rules lets an insurer and a provider agree Pay for Quality indicators in their contract, and names 30-day readmission as one of them. Performance is measured against other providers, and can result in additional payment. It is negotiation upside rather than penalty avoidance — a different conversation from the American one, and a better one.

Does JAWDA Data Certification reward lower readmissions?

No, and this is worth separating carefully. JAWDA Data Certification does affect reimbursement — certified facilities may bill Evaluation and Management codes at negotiated rates up to three times the mandatory tariff, while uncertified facilities bill at the lowest level of the E&M category. But that is triggered by clinical documentation and coding quality, not by readmission performance. Anyone telling you JAWDA reimbursement is a reason to reduce readmissions is joining two unrelated mechanisms.

Does the Pay for Quality clause apply to every contract?

No. It is opt-in and must be mutually agreed into the contractual agreement, it excludes Basic Products, and readmission rates are measured in hospitals only. It also runs both ways — performance against peers can mean additional payment or a reduction, and a weaker result on one indicator can be offset by a stronger one on another.

Do you handle Malaffi, NABIDH and Riayati?

Ask us before assuming. Malaffi is Abu Dhabi’s health information exchange, NABIDH is Dubai’s, and Riayati is federal — different systems under different authorities. What OneDose connects to today varies by deployment, and we would rather confirm it in writing for your emirate and your estate than publish a claim on a page.

United Arab Emirates

In the UAE, readmissions aren’t a penalty. They’re a negotiating position.

No UAE authority penalises a hospital for readmissions, and under DRG a readmission is paid as a new admission — so it earns you revenue. What Abu Dhabi does have is §2.4 of the DoH Claims and Adjudication Rules, which lets an insurer and a provider agree 30-day readmission as a Pay for Quality indicator: beat your peers and the contract can pay you more.

OneDose runs the structured post-discharge follow-up that produces that performance — on every discharge, not the few a rota had room for.

Book a 30-min demo

Why the American version of this pitch doesn't work here

In the United States, this is a simple conversation. CMS runs the Hospital Readmissions Reduction Program, excess 30-day readmissions cost a hospital up to 3% of its Medicare payments, and the CFO takes the meeting because there is a fine.

None of that is true here, and it is worth saying plainly because the entire category imports the American argument without checking. There is no readmission penalty in the UAE. Inpatient care is reimbursed by DRG per admitted episode, and no rule bundles a readmission back into the original one — so a readmission is admitted, coded and paid as a new episode.

Which means that, as your reimbursement is currently structured, a readmission makes you money. Any vendor telling you to reduce readmissions to protect revenue has the sign backwards, and you should ask them which regulation they think they are describing.

The clearest evidence is what the Department of Health chose not to do. It already operates outcome-based non-payment: when a Hospital-Acquired Condition is acquired during a stay, the provider does not receive the higher payment. DoH knows exactly how to build a payment penalty for a bad clinical outcome. It built one. It did not build one for readmissions.

What Abu Dhabi has instead — and it's better

Section 2.4 of the DoH Claims and Adjudication Rules lets insurers and providers agree Pay for Quality indicators inside their contract. Three clinical outcome indicators are named, and one of them is 30-day readmission.

Performance is assessed against other providers, and can result in additional payment. So the question stops being “how do I avoid a fine” and becomes “what is my readmission performance worth at the next contract round” — which is a conversation a CFO can actually act on, and one where a good number is an asset rather than the absence of a liability.

The mechanics matter, and we would rather you hear them from us than discover them later. It is opt-in and has to be mutually agreed into the contract. It excludes Basic Products. Readmission is measured in hospitals only. And it runs both ways — peer performance can mean additional payment or a reduction, and a weak indicator can be offset by a strong one elsewhere.

The plumbing is already there. §2.4 wants indicators verifiable through an independent source or centrally available via the Health Authority — and 30-day unplanned readmission is already a JAWDA KPI you report quarterly. You are measuring the number. The clause decides whether it is worth anything.

Doesn't JAWDA already affect our reimbursement?

It does — and it has nothing to do with readmissions. This distinction is the one we most often see collapsed, usually by someone selling something.

JAWDA Data Certification is real money. A certified facility can bill Evaluation and Management codes at negotiated rates up to three times the mandatory tariff. An uncertified one bills doctor’s visits at the lowest level of the E&M category. That is a material difference on every consultation you invoice.

But it is triggered by clinical documentation and coding quality, audited as such. Your readmission rate does not feed it, and it does not reward your readmission rate. “JAWDA affects your reimbursement, therefore fix your readmissions” joins two unrelated mechanisms: both halves are true and the join is false.

We are not selling you a JAWDA certification lever. We are pointing at §2.4, which is a different clause in the same document and is actually about readmissions.

What about Dubai?

Dubai has no equivalent. DHA has run IR-DRG since 2020, and there are no readmission provisions in its current DRG parameters, its benefit plan terms, or its claim audit and recovery rules — where the triggers are fraud, waste and abuse. Dubai’s payment formula contains no quality term at all. The Abu Dhabi hook does not transfer across the emirates.

You may have heard otherwise. The claim that Dubai penalises readmissions or requires unpaid follow-up traces back to a single uncited social media post from 2021 with no DHA regulation behind it. We mention it only because it circulates, and because a vendor repeating it to you is telling you something useful about the vendor.

DHA’s EJADAH programme is a genuine move from volume to value, and DHA has said publicly it intends to pay for outcomes that matter to patients. But the programme materials do not mention readmission, discharge or follow-up. That is direction of travel, not a lever you can pull this year.

So what is the honest case for a Dubai or Northern Emirates hospital?

Not a financial one we can point at a regulation for. If your reimbursement carries no quality term, we are not going to invent one for you.

What is left is the argument that was always the real one, and it does not depend on a regulator: the patient nobody had time to call is a patient nobody is observing. Your 30-day readmission rate is published and rated. Muashir scores it, DoH publishes it, and DoH itself ties that transparency to positioning the emirate for medical tourism. The number is visible whether or not it is priced.

If that is not enough to justify the spend at your organisation, that is a legitimate answer and we would rather you reach it before a procurement cycle than during one.

Frequently asked

Is there a readmission penalty in the UAE?: No. Neither the Department of Health in Abu Dhabi nor the Dubai Health Authority penalises a hospital for excess 30-day readmissions. Because inpatient care is reimbursed by DRG per admitted episode, and no rule bundles a readmission into the original episode, a readmission is admitted and paid as a new one. It earns the hospital revenue rather than costing it.
Then why would a UAE hospital reduce readmissions?: Because Abu Dhabi lets you get paid for it. Section 2.4 of the DoH Claims and Adjudication Rules lets an insurer and a provider agree Pay for Quality indicators in their contract, and names 30-day readmission as one of them. Performance is measured against other providers, and can result in additional payment. It is negotiation upside rather than penalty avoidance — a different conversation from the American one, and a better one.
Does JAWDA Data Certification reward lower readmissions?: No, and this is worth separating carefully. JAWDA Data Certification does affect reimbursement — certified facilities may bill Evaluation and Management codes at negotiated rates up to three times the mandatory tariff, while uncertified facilities bill at the lowest level of the E&M category. But that is triggered by clinical documentation and coding quality, not by readmission performance. Anyone telling you JAWDA reimbursement is a reason to reduce readmissions is joining two unrelated mechanisms.
Does the Pay for Quality clause apply to every contract?: No. It is opt-in and must be mutually agreed into the contractual agreement, it excludes Basic Products, and readmission rates are measured in hospitals only. It also runs both ways — performance against peers can mean additional payment or a reduction, and a weaker result on one indicator can be offset by a stronger one on another.
Do you handle Malaffi, NABIDH and Riayati?: Ask us before assuming. Malaffi is Abu Dhabi’s health information exchange, NABIDH is Dubai’s, and Riayati is federal — different systems under different authorities. What OneDose connects to today varies by deployment, and we would rather confirm it in writing for your emirate and your estate than publish a claim on a page.